ATE326537T1 - Schnell erzeugung von stabilen säugertier- zellinien mit gewinnung eines hohen gehalts von recombinanten proteine - Google Patents

Schnell erzeugung von stabilen säugertier- zellinien mit gewinnung eines hohen gehalts von recombinanten proteine

Info

Publication number
ATE326537T1
ATE326537T1 AT98953816T AT98953816T ATE326537T1 AT E326537 T1 ATE326537 T1 AT E326537T1 AT 98953816 T AT98953816 T AT 98953816T AT 98953816 T AT98953816 T AT 98953816T AT E326537 T1 ATE326537 T1 AT E326537T1
Authority
AT
Austria
Prior art keywords
cell lines
recombinant proteins
high content
obtaining high
generate stable
Prior art date
Application number
AT98953816T
Other languages
English (en)
Inventor
Kathleen Tomkinson
Monique Davies
John Mccoy
Original Assignee
Genetics Inst Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst Llc filed Critical Genetics Inst Llc
Application granted granted Critical
Publication of ATE326537T1 publication Critical patent/ATE326537T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT98953816T 1997-10-29 1998-10-21 Schnell erzeugung von stabilen säugertier- zellinien mit gewinnung eines hohen gehalts von recombinanten proteine ATE326537T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6344997P 1997-10-29 1997-10-29
US09/175,690 US6136536A (en) 1997-10-29 1998-10-20 Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins

Publications (1)

Publication Number Publication Date
ATE326537T1 true ATE326537T1 (de) 2006-06-15

Family

ID=26743435

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98953816T ATE326537T1 (de) 1997-10-29 1998-10-21 Schnell erzeugung von stabilen säugertier- zellinien mit gewinnung eines hohen gehalts von recombinanten proteine

Country Status (12)

Country Link
US (1) US6136536A (de)
EP (1) EP1025245B1 (de)
JP (2) JP2001520882A (de)
AT (1) ATE326537T1 (de)
AU (1) AU740768B2 (de)
CA (1) CA2306449C (de)
CY (1) CY1105290T1 (de)
DE (1) DE69834565T2 (de)
DK (1) DK1025245T3 (de)
ES (1) ES2263225T3 (de)
PT (1) PT1025245E (de)
WO (1) WO1999021976A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083378A2 (en) * 2003-03-17 2004-09-30 Emory University Mammalian cell lines specifically deficient in o-linked glycosylation
KR100533794B1 (ko) * 2003-10-02 2005-12-07 주식회사 프로젠 인간 난포자극 호르몬을 대량으로 생산하는 방법
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
WO2005056752A2 (en) 2003-10-24 2005-06-23 Gencia Corporation Methods and compositions for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
ES2642214T3 (es) 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
AU2007352618B2 (en) 2007-05-02 2013-07-18 Boehringer Ingelheim Animal Health USA Inc. DNA plasmids having improved expression and stability
US20090123494A1 (en) * 2007-07-31 2009-05-14 William Staplin Momlv-based pseudovirion packaging cell line
AU2009279090A1 (en) * 2008-08-06 2010-02-11 Novo Nordisk Health Care Ag Conjugated proteins with prolonged in vivo efficacy
CA2747825A1 (en) 2009-01-22 2010-07-29 Novo Nordisk Health Care Ag Stable growth hormone compounds
EP2461831B1 (de) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Wachstumshormone mit verlängerter in-vivo-wirksamkeit
RU2605627C2 (ru) 2010-01-22 2016-12-27 Ново Нордиск Хелс Кеа Аг Гормоны роста с пролонгированной эффективностью in vivo
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
JP2013533264A (ja) 2010-07-22 2013-08-22 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモンコンジュゲート
EP2981282B1 (de) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Wachstumshormonverbindungsformulierung
PL3218514T3 (pl) 2014-11-12 2020-01-31 Lek Pharmaceuticals D.D. Przewidywanie genetycznie stabilnej produkcji rekombinowanego białka we wczesnym rozwoju linii komórkowej

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740461A (en) * 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5550036A (en) * 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US5094953A (en) * 1988-03-21 1992-03-10 Genentech, Inc. Human tissue plasminogen activator variants
JPH08505534A (ja) * 1993-01-13 1996-06-18 森永乳業株式会社 Ｍ−ｃｓｆ２２３の製造方法
DE69420033T2 (de) * 1993-04-06 1999-12-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Bethesda Gibbon leukemia virus retrovirale vektoren
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US6004941A (en) * 1993-06-14 1999-12-21 Basf Aktiengesellschaft Methods for regulating gene expression
CA2165162C (en) * 1993-06-14 2000-05-23 Hermann Bujard Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5866755A (en) * 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
JPH08305625A (ja) * 1995-05-11 1996-11-22 Hitachi Ltd 演算処理機能付き半導体メモリ及びそれを用いた処理装置
US5891718A (en) * 1996-03-27 1999-04-06 Vical Incorporated Tetracycline inducible/repressible systems

Also Published As

Publication number Publication date
US6136536A (en) 2000-10-24
AU1109199A (en) 1999-05-17
DE69834565D1 (de) 2006-06-22
WO1999021976A2 (en) 1999-05-06
CA2306449A1 (en) 1999-05-06
AU740768B2 (en) 2001-11-15
DE69834565T2 (de) 2007-04-26
ES2263225T3 (es) 2006-12-01
EP1025245B1 (de) 2006-05-17
EP1025245A2 (de) 2000-08-09
CY1105290T1 (el) 2010-03-03
DK1025245T3 (da) 2006-08-21
WO1999021976A3 (en) 1999-07-08
JP2001520882A (ja) 2001-11-06
PT1025245E (pt) 2006-08-31
JP2010000087A (ja) 2010-01-07
CA2306449C (en) 2008-12-16

Similar Documents

Publication Publication Date Title
DE69834565D1 (de) Schnell erzeugung von stabilen säugertier-zellinien mit gewinnung eines hohen gehalts von recombinanten proteine
ATE295416T1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
DE69836092D1 (de) Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
DK0941352T3 (da) Forbedring af stivelsesindholdet i planter
AR018023A1 (es) Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada
DK0973819T3 (da) Ikke-antigene forgrenede polymerkonjugater
DK1210411T3 (da) Sammensætninger og fremgangsmåder til forbedret celledyrkning
DE69734395D1 (de) Verbesserte chondrogene differenzierung von menschlichen mesenchym-stammzellen
DK0643767T3 (da) Osteogene peptider
DK1137808T3 (da) Fremgangsmåde til fremstilling af rekombinante celler
DK0770088T3 (da) Hidtil ukendt cytokin betegner LERK-5.
DE69032809D1 (de) Herstellung von Proteinen mittels homologer Rekombination
DE69933550D1 (de) Modifizierte adenoviren welche ein faserersatzprotein enthalten
ATE531789T1 (de) Zellmembranenveränderung
DK1088084T3 (da) Erythropoietin analog-humant serumalbumin fusionsprotein
NO952039L (no) Proteiner med glykosyltransferase-aktivitet
ES2153358T3 (es) Procedimientos para la seleccion de celulas huespedes recombinantes que expresan altos niveles de una proteina deseada.
ATE173295T1 (de) Ecdysteroid-abhängige gen regulierung in säugetier-zellen
DK0843731T3 (da) Adenovirusvektorer til genterapi
EP0820311A4 (de) Transplantation von genetisch veränderten zellen mit einem niedrigen gehalt von klasse i mhc proteinen auf ihrer zelloberfläche
DK0658626T3 (da) Fremgangsmåder til produktion af protein C
ATE96838T1 (de) Expressionsvektor und verfahren zur expression von heterologen proteinen in saeugerzellen.
DE69535024D1 (de) Verpackungszellinie zur transkomplementierung von defektiven retroviren-vektoren
DE69737597D1 (de) Vektoren zur inhibierung von viralem und tumorwachstum
DK0994955T3 (da) Öget produktion af secernerede proteiner med rekombinante gærceller

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1025245

Country of ref document: EP

REN Ceased due to non-payment of the annual fee